Back to top
more

Quanterix (QTRX)

(Delayed Data from NSDQ)

$15.36 USD

15.36
465,868

-0.11 (-0.71%)

Updated Jun 5, 2024 04:00 PM ET

After-Market: $15.35 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 248)

Industry: Medical - Products

Better trading starts here.

Zacks News

Zimmer Biomet (ZBH) Business Recovery Continues Despite FX Woe

Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.

LivaNova (LIVN) Advances Cardiopulmonary Wing With Essenz ILBM

LivaNova's (LIVN) Essenz ILBM boasts B-Capta sensing technology, ensuring accuracy and compliance with Clinical Laboratory Improvement Amendments.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

A diversified product portfolio and a broad geographic footprint bode well for Teleflex (TFX).

Globus Medical (GMED) Completes NuVasive Merger Agreement

Globus Medical's (GMED) recent deal combines complementary spine and orthopedic solutions, enabling technologies to create one of the industry's most comprehensive, innovative offerings.

ICU Medical's (ICUI) Plum Duo With Safety Shield Gets 510(k) Nod

The Plum Duo infusion pump represents the latest addition to ICU Medical's (ICUI) advanced lineup of infusion devices.

Neogen (NEOG) Launches SureKill Evolve SC Pest Management Tool

Neogen (NEOG) introduces the latest solution in the SureKill brand of products, SureKill Evolve SC.

Boston Scientific's (BSX) FARAPULSE System Study Data Positive

Boston Scientific's (BSX) FARAPULSE PFA System's performance in the trial is an encouraging sign of the potential utilization of the device in the United States.

Quest Diagnostics' (DGX) AAV Test Gets FDA's Breakthrough Nod

Quest Diagnostics (DGX) achieves breakthrough designation for AAVrh74 ELISA and expands collaboration with Sarepta Therapeutics.

Walgreens (WBA) OTC NARCAN Nasal Spray to be Available Soon

Walgreens (WBA) is instructing Americans to administer this life-saving drug that, if given in time, can reverse the effects of an opioid overdose.

Abbott's (ABT) Libre Gains Momentum Amid Low Testing Sales

Banking on the successful execution of Abbott's (ABT) branded generic operating model, EPD is well positioned for sustained growth in many of the growing pharmaceutical markets.

Inspira (IINN) Advances Foothold in Europe With Extended Deal

The extended service agreement complements a previously announced strategic agreement between Inspira (IINN) and Innovimed.

Here's Why You Should Retain Integra (IART) Stock for Now

Investors continue to be optimistic about Integra (IART) based on the prospects of its CSS segment and a stable liquidity position.

Exact Sciences' (EXAS) OncoExtra Test Selected for ComboMATCH

Exact Sciences' (EXAS) Laboratory and OncoExtra test gets selected by the NCI for ComboMATCH trials.

Here's Why You Should Invest in Neogen (NEOG) Stock Now

Investors are optimistic about Neogen (NEOG) on recent product launches.

STERIS (STE) Banks on New Pact for Growth Amid Rising Expenses

Continuous procedure volume growth in the United States, favorable pricing and market share gains are driving STERIS' (STE) Healthcare segment organic growth.

Haemonetics (HAE) Expands VASCADE System Portfolio in Germany

Haemonetics (HAE) announces the first treatment of patients in Germany with the VASCADE MVP Venous Vascular Closure system.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

Investors are optimistic about Zimmer Biomet (ZBH) due to innovative new product launches and solid execution.

Insulet (PODD) Launches Omnipod 5 AID System in Germany

Insulet's (PODD) Omnipod 5 is available in the United States and the United Kingdom.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

Investors are optimistic about Henry Schein (HSIC), led by the strength of its dental business.

Orthofix's (OFIX) New Launch to Benefit the MIS Spine Market

Orthofix (OFIX) announces the commercial launch and the successful completion of the first cases in the United States with the 7D FLASH Navigation System Percutaneous Module 2.0.

Syneos Health (SYNH) Expands Catalyst Site Program to China

Syneos Health (SYNH) announces a collaboration with China's Wuhan Union Hospital, expanding clinical trial capabilities.

Integra (IART) CSS Sales Aid, Boston Recall Hurts Growth

In spite of facing foreign exchange fluctuations across its non-U.S. business, Integra (IART) is successfully broadening its international footprint.

BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model

BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.

Thermo Fisher's (TMO) EXTENT Solution Makes Commercial Launch

Thermo Fisher (TMO) announces the commercial launch of the EXTENT Solution with IVDR certification.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.